Skye Bioscience, Inc. (SKYE) Stock Analysis & Investment Frameworks
Skye Bioscience, Inc. (SKYE) stock analysis on Invetso. Review Skye Bioscience, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Skye Bioscience, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Skye Bioscience, Inc. Key Financial Metrics
- Market Cap: $6.86M
- Revenue: $N/A
- ROE: -329.08%
- ROIC: 11242.31%
- Dividend Yield: N/A
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Skye Bioscience, Inc. Investment Frameworks
Invetso analyzes Skye Bioscience, Inc. (SKYE) across the following frameworks:
- Skye Bioscience, Inc. 10Y Growth Potential
- Skye Bioscience, Inc. Scenario Analysis
- Skye Bioscience, Inc. Risks & Opportunities
- Skye Bioscience, Inc. Economic Moat
- Skye Bioscience, Inc. Business Model
- Skye Bioscience, Inc. Management
- Skye Bioscience, Inc. SWOT Analysis
- Skye Bioscience, Inc. Porter's 5 Forces
- Skye Bioscience, Inc. PESTLE Analysis
- Skye Bioscience, Inc. ESG Analysis